Copyright
©The Author(s) 2016.
World J Hepatol. Jun 18, 2016; 8(17): 703-715
Published online Jun 18, 2016. doi: 10.4254/wjh.v8.i17.703
Published online Jun 18, 2016. doi: 10.4254/wjh.v8.i17.703
Table 4 Barcelona Clinic Liver Cancer C hepatocellular carcinoma, a broad spectrum of tumors; example of the Advanced Liver Cancer Prognostic System score[36]
Parameters | Points |
Ascites | 2 |
Abdominal pain | 2 |
Weight loss | 2 |
Child-Pugh grade A/B/C | 0/2/5 |
alkaline phosphatase, UI/L > 200 | 3 |
Bilirubin, mcmol/L ≤ 33/> 33- ≤ 50/> 50 | 0/1/3 |
Urea, mmol/L > 8.9 | 2 |
Portal vein thrombosis | 3 |
Tumor size: Diffuse/> 5 cm/ ≤ 5 cm | 4/3/0 |
Lung metastases | 3 |
AFP, ng/mL > 400 | 4 |
Probability of patients surviving at least 3 mo estimated by the ALCPS score[36] | |
Score ≤ 8 points: 82.0% (95%CI: 76.5%-87.5%) | |
Score 9-15 points: 53.4% (95%CI: 48.3%-57.7%) | |
Score ≥ 16 points: 18.9% (95%CI: 14.7%-23.3%) |
- Citation: Adhoute X, Penaranda G, Raoul JL, Le Treut P, Bollon E, Hardwigsen J, Castellani P, Perrier H, Bourlière M. Usefulness of staging systems and prognostic scores for hepatocellular carcinoma treatments. World J Hepatol 2016; 8(17): 703-715
- URL: https://www.wjgnet.com/1948-5182/full/v8/i17/703.htm
- DOI: https://dx.doi.org/10.4254/wjh.v8.i17.703